A Phase 3 interventional study of Obinutuzumab and MMF in Childhood Idiopathic Nephrotic Syndrome, sponsored by Hoffmann-La Roche. Completed at 35 sites in 9 countries. Open to participants aged 2 Years to 25 Years. Per ClinicalTrials.gov, last updated 2026-10-14.
Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 51 studies in Nephrotic Syndrome with a site in United States — 12 open to participants now, 13 under way, none of them phase 3. Nephrotic Syndrome · United States.
Among the 51 studies in Nephrotic Syndrome with a site in United States, this one is the 7th largest by enrollment of the 38 interventional ones that give a count, is one of 3 that started in 2023, is one of 4 in phase 3, and was the 48th registered.
192 studies on the registry are indexed under Nephrotic Syndrome; 65 are open to participants now.
Browse Nephrotic Syndrome studies →12 of the 51 studies in Nephrotic Syndrome with a site in United States are open now. Recruiting first, the newest first:
Vera Therapeutics, Inc. · Sites in United States
Ages 2+
University of California, San Francisco · Sites in United States
Healthy volunteers
University of California, San Francisco · Sites in United States
University of Texas Southwestern Medical Center · Sites in United States
Ages 18+
University of Michigan · Sites in United States
Ages 1–80
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 50 Nephrotic Syndrome studies recruiting now, 23 (46%) set no upper age limit and 22 (44%) stop at 75 or younger; 37 take children under 18; 4 take healthy volunteers.
This study: 2 Years to 25 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
51 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 19 · Phase 3 5 · Phase 4 5
First in 1986; this study’s year is marked. 3 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 85 is above the median of 46 across 122 interventional studies indexed under Nephrotic Syndrome.
Median enrollment 26 across the 38 interventional studies, 168 across the 12 observational. Of the 36 that completed or were terminated, 13 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 51 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 331 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
Hoffmann-La Roche has 1 study filed under Nephrotic Syndrome — fewer than ten, so there is no comparison to draw.
2 of the studies in Nephrotic Syndrome with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04885179University of California, San FranciscoSPL Insufficiency Syndrome (SPLIS)/NPHS14: a SPLIS Observational Study and Patient Registry (International) | 2026-12-30 |
| NCT06983028Vera Therapeutics, Inc.Atacicept in Multiple Glomerular Diseases | 2027-11 |
Add all 2 to your calendar (.ics) → With an account.
Among the 51 studies in Nephrotic Syndrome with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This open-label, randomized multicenter study is to assess the efficacy, safety, and pharmacokinetics (PK)/pharmacodynamics (PD) of obinutuzumab compared with mycophenolate mofetil (MMF) in children and young adults (aged >= 2-25 years) with frequently relapsing nephrotic syndrome (FRNS) or steroid-dependent nephrotic syndrome (SDNS).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in Group A will receive obinutuzumab 1000 milligrams (mg) (or 20 mg/ kilogram \[kg\] for participants \<45 kg) administered by intravenous (IV) infusion on Days 1, 15, 168 (Week 24), and 182 (Week 26).
Drug: Obinutuzumab · Drug: Prednisone · Drug: Methylprednisolone · Drug: Acetaminophen/ Paracetamol · Drug: Diphenhydramine Hydrochloride
Participants in Group B will receive oral MMF 600 mg/m\^2 twice a day (BID) (target 1200 mg/m2/day in divided doses, maximum 2 g/day) to Week 52.
Drug: MMF · Drug: Prednisone
Obinutuzumab will be administered as per schedule specified in the respective arm.
MMF will be administered as per schedule specified in the respective arm.
Participants taking prednisone or equivalent at randomization will follow a guided tapering schedule to reach the goal of 0mg/day by Weeks 4-6 (and no later than Week 8 following randomization and continue without prednisone through Week 52.
Also known as: Non-Investigational Medicinal Product
Methylprednisolone 80 mg (or 1.5 mg/kg if \</=45 kg) IV will be administered as premedication prior to infusions.
Also known as: Non-Investigational Medicinal Product
Drug page: Acetaminophen
Acetaminophen 15 mg/kg (maximum dose 1000 mg) will be administered PO as premedication prior to infusions.
Also known as: Non-Investigational Medicinal Product
Diphenhydramine HCl 0.5-1 mg/kg (maximum dose 50 mg) will be administered PO or IV as premedication prior to infusions.
Also known as: Non-Investigational Medicinal Product
Percentage of Participants With Sustained Complete Remission at Week 52
Sustained complete remission was defined as first morning void urine protein-to-creatinine ratio (UPCR) ≤0.2 gram/gram (g/g) at Week 52 without the occurrence of relapse or any other intercurrent event (IE) (except treatment discontinuation for any reason \[TDAR\]). Participants with following IE were considered non-responders (except TDAR): After Week 8: 1) Relapse=Any of the following events: First-morning void UPCR ≥ 2 g/g; or dipstick urinalysis (UA) ≥3+ for 3 consecutive days (home-monitoring) \& most recent urine sample determined to have UPCR \>0.2 g/g as measured by the central laboratory ; or dipstick UA protein ≥ 3+ on any single day with edema \& urine sample determined to have UPCR \> 0.2 g/g as measured by the central laboratory. 2) Any systemic corticosteroids usage for \>14 days in 30-day period. After randomization: 1) Initiation of any rescue therapy for idiopathic nephrotic syndrome (INS), as per investigator other than systemic corticosteroids. 2) Death.
Time frame: At Week 52
Overall Relapse-free Survival (RFS)
Overall RFS was defined as the time from randomization to first relapse or death. Relapse was defined as any of the following events: First-morning void UPCR ≥2 g/g; or dipstick UA ≥3+ for 3 consecutive days (home-monitoring) and the most recent urine sample determined to have UPCR \>0.2 g/g as measured by the central laboratory; or dipstick UA protein ≥3+ on any single day with edema and urine sample determined to have UPCR \> 0.2 g/g as measured by the central laboratory. Participants who withdrew their consent were censored at the time of withdrawal. Participants who were lost to follow-up were censored at the last assessment during scheduled or unscheduled visits. Kaplan-Meier (KM) estimates were used to evaluate the median RFS.
Time frame: Up to approximately 127.3 weeks
Cumulative Corticosteroid Dose From Baseline to Week 52
Cumulative corticosteroid dose was defined as the total dose received (mg/kg) of prednisone or equivalent, regardless of intercurrent events (relapse, rescue therapy, treatment discontinuation for any reason, and systemic corticosteroid usage for \> 14 days) in participants prior to experiencing death. Topical, intraarticular, or inhaled corticosteroids and IV methylprednisolone given as a pre-medication were not included in this analysis.
Time frame: Baseline up to Week 52
Relapses From Baseline to Week 52
Relapses were evaluated using adjusted rate ratio from baseline to Week 52, regardless of IEs (relapse, TDAR \& systemic corticosteroid usage for \>14 days) in participants before receiving rescue therapy (RT)/experiencing death. Total number of relapses occurring during treatment period were evaluated by accounting for number of relapses experienced \& participant's follow-up time. Participant level relapse \& follow-up time data were aggregated, \& rate of relapses was compared between the two arms. Rate of relapse was analyzed using a negative binomial model with a log link \& log of each participant's follow up time as offset variable. Relapse=any of the following events: First-morning void UPCR ≥2 g/g; or dipstick UA ≥3+ for 3 consecutive days (home-monitoring) \& most recent urine sample determined to have UPCR \>0.2 g/g as measured by the central laboratory; or dipstick UA protein ≥ 3+ on any single day with edema \& urine sample determined to have UPCR \>0.2 g/g per central laboratory.
Time frame: Baseline up to Week 52
Percentage of Participants With Sustained Complete Remission at Week 76
Sustained complete remission=first morning void UPCR ≤ 0.2 g/g at Week 76 without the occurrence of relapse or any other IE (except TDAR). Relapse=Any of the following events: First-morning void UPCR ≥ 2 g/g; or dipstick UA ≥3+ for 3 consecutive days (home-monitoring) \& the most recent urine sample determined to have UPCR \> 0.2 g/g as measured by the central laboratory; or dipstick UA protein ≥ 3+ on any single day with edema \& urine sample determined to have UPCR \> 0.2 g/g as measured by the central laboratory. Other IEs include: Any systemic corticosteroids usage for \>14 days in a 30 day period; Initiation of any rescue therapy for INS, other than systemic corticosteroids; Death or TDAR. Participants with FRNS/SDNS who were randomized into the study at least 24 weeks prior to the date of randomization for the final participant in the study were only analyzed in this endpoint. Percentages have been rounded off.
Time frame: At Week 76
Probability of RFS at Week 52
Probability of RFS at Week 52 was defined as the percentage of participants remaining free of relapse or death at Week 52. Relapse was defined as any of the following events: First-morning void UPCR ≥2 g/g; or dipstick UA ≥3+ for 3 consecutive days (home-monitoring) and the most recent urine sample determined to have UPCR \> 0.2 g/g as measured by the central laboratory; or dipstick UA protein ≥ 3+ on any single day with edema and urine sample determined to have UPCR \> 0.2 g/g as measured by the central laboratory. Participants who withdrew their consent were censored at the time of withdrawal. Participants who were lost to follow-up were censored at the last assessment during scheduled or unscheduled visits. K-M method was used to estimate the RFS rate at Week 52. Percentages have been rounded off.
Time frame: At Week 52
Percentage of Participants Experiencing Edema Associated Relapse During the 52-week Treatment Period
Edema-associated relapse definition is the same as the definition of relapse except that the edema-associated relapse definition additionally requires that participant edema is present and documented in the eCRF at the time of the relapse event. Relapse=any of the following events: First-morning void UPCR ≥ 2 g/g; or dipstick UA ≥3+ for 3 consecutive days (home-monitoring) \& the most recent urine sample determined to have UPCR \> 0.2 g/g, measured by the central laboratory; or dipstick UA protein ≥ 3+ on any single day with edema \& urine sample determined to have UPCR \> 0.2 g/g as measured by the central laboratory. Percentages have been rounded off.
Time frame: Baseline up to Week 52
Mean Change From Baseline to Week 52 in Cure Glomerulonephropathy Network (CureGN) Edema Scale
Mean Change in CureGN Edema scale was defined as the mean change in total edema severity from baseline to Week 52, regardless of relapse, systemic corticosteroids usage for \>14 days in a 30 day period, and treatment discontinuation due to any reason, in participants prior to receiving rescue therapy and assuming death has not occurred. The CureGN edema scale was used to assess the total edema severity. Participants were asked to report the location of edema they experienced over the last month from eight different body areas (whole body, face, hands, arms, abdomen, genitalia, legs, feet) and rate its severity on a 6-point Likert scale (0=absent to 5=worst imaginable), with total scores ranging from 0-40. Higher score indicated worst edema severity. Adjusted mean change in the CureGN edema scale scores from baseline to Week 52 has been reported.
Time frame: Baseline up to Week 52
Mean Change From Baseline to Week 52 in "General Fatigue" Domain of Pediatric Quality of Life Inventory (PedsQL)-Multidimensional Fatigue Scale (MFS) Total Score
Mean Change in "General Fatigue" domain of PedsQL-MFS total score was defined as the mean change in total score of the "General Fatigue" domain from baseline to Week 52, regardless of relapse, systemic corticosteroids usage for \>14 days in a 30-day period, \& treatment discontinuation due to any reason, in participants prior to receiving rescue therapy \& assuming death did not occur. PedsQL MFS is an 18-item, self-reported measure designed to assess fatigue in participants with acute or chronic health conditions. This was a standard version with a 1-month recall period. The measure assessed three components of fatigue: General Fatigue (6 items), Sleep/Rest Fatigue (6 items), \& Cognitive Fatigue (6 items). General fatigue scores were based on a 5-point Likert response format, ranging from 0 (Never) to 4 (Almost Always) \& transformed to 0-100 total score. Higher score=less fatigue. Adjusted mean change in general fatigue domain scores from baseline to Week 52 has been reported.
Time frame: Baseline up to Week 52
Mean Change From Baseline to Week 52 in "Physical Functioning (PF)" Domain of PedsQL-4.0 Generic Core Scale
Mean Change in PF domain of PedsQL = mean change in the PF score from baseline to Week 52, regardless of relapse, systemic corticosteroids usage for \>14 days in a 30-day period, \& treatment discontinuation due to any reason, in participants prior to receiving rescue therapy \& assuming death did not occur. The PedsQL 4.0 Generic Core Scale is a 23 item measure used to assess health-related quality of life, over a recall of either one month (standard version) or 7 days (acute version). The 4 core domains include PF (8 items), Emotional Functioning (5 items), Social Functioning (5 items), and School Functioning (5 items). Items are rated on a 5-point Likert scale ranging from 0 (never a problem) to 4 (almost always a problem). Once completed, items are reverse scored \& linearly transformed to 0-100 scale as follows: 0=100, 1=75, 2=50, 3=25, 4=0, with higher scores=better health-related quality of life. Adjusted mean change in PF domain scores from baseline to Week 52 has been reported.
Time frame: Baseline up to Week 52
52-week Treatment Period: Number of Participants With Adverse Events (AEs)
An AE was defined as any untoward medical occurrence in a participant or clinical study participant temporally associated with the use of a study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study intervention. As pre-specified in the SAP, analysis excludes AEs reported following rescue treatment other than corticosteroids.
Time frame: Up to Week 52
Maximum Serum Concentration (Cmax) of Obinutuzumab
Samples were collected pre- and post-infusion at Weeks 0, 2, 24, and 26 and single samples were collected at Weeks 4, 12, 32, and 52. Data reported is averaged over the weeks specified in the time frame.
Time frame: Weeks 0-24 and Weeks 24-52
Trough Concentration (Ctrough) of Obinutuzumab
Samples were collected pre- and post-infusion at Weeks 0, 2, 24, and 26 and single samples were collected at Weeks 4, 12, 32, and 52. Data reported is averaged over the weeks specified in the time frame.
Time frame: Weeks 0-24 and Weeks 24-52
Area Under the Concentration-Time Curve of Obinutuzumab From Time 0 to 52 Weeks (AUC0-52)
Samples were collected pre- and post-infusion at Weeks 0, 2, 24, and 26 and single samples were collected at Weeks 4, 12, 32, and 52. Data reported is averaged over the weeks specified in the time frame.
Time frame: Weeks 0-52
Percentage of Participants Achieving B-cell Depletion Analyzed Using High Sensitivity Flow Cytometry (HSFC) Over Time
Time frame: Up to approximately 3 years
Total Peripheral B-cell and B-cell Subsets Counts Over Time
Time frame: Up to approximately 3 years
Change From Baseline in Total Peripheral B-cell and B-cell Subsets Counts
Time frame: Baseline up to approximately 3 years
A total of 85 participants with childhood onset of frequently relapsing nephrotic syndrome (FRNS) or steroid-dependent nephrotic syndrome (SDNS) took part in the study at 32 investigative sites across 9 countries. The study is still ongoing.
| Milestone | Obinutuzumab | Mycophenolate Mofetil |
|---|---|---|
| Started | 44 | 41 |
| Completed | 1 | 3 |
| Not completed | 43 | 38 |
| Withdrew: Physician decision | 0 | 1 |
| Withdrew: Withdrawal by subject | 1 | 0 |
| Withdrew: Ongoing in study | 42 | 37 |
Sustained complete remission was defined as first morning void urine protein-to-creatinine ratio (UPCR) ≤0.2 gram/gram (g/g) at Week 52 without the occurrence of relapse or any other intercurrent event (IE) (except treatment discontinuation for any reason \[TDAR\]). Participants with following IE were considered non-responders (except TDAR): After Week 8: 1) Relapse=Any of the following events: First-morning void UPCR ≥ 2 g/g; or dipstick urinalysis (UA) ≥3+ for 3 consecutive days (home-monitoring) \& most recent urine sample determined to have UPCR \>0.2 g/g as measured by the central laboratory ; or dipstick UA protein ≥ 3+ on any single day with edema \& urine sample determined to have UPCR \> 0.2 g/g as measured by the central laboratory. 2) Any systemic corticosteroids usage for \>14 days in 30-day period. After randomization: 1) Initiation of any rescue therapy for idiopathic nephrotic syndrome (INS), as per investigator other than systemic corticosteroids. 2) Death.
| percentage of participants | Obinutuzumab | Mycophenolate Mofetil |
|---|---|---|
| Percentage of Participants With Sustained Complete Remission at Week 52 | 95.5 (89.30 to 100.00) | 73.2 (59.61 to 86.73) |
Overall RFS was defined as the time from randomization to first relapse or death. Relapse was defined as any of the following events: First-morning void UPCR ≥2 g/g; or dipstick UA ≥3+ for 3 consecutive days (home-monitoring) and the most recent urine sample determined to have UPCR \>0.2 g/g as measured by the central laboratory; or dipstick UA protein ≥3+ on any single day with edema and urine sample determined to have UPCR \> 0.2 g/g as measured by the central laboratory. Participants who withdrew their consent were censored at the time of withdrawal. Participants who were lost to follow-up were censored at the last assessment during scheduled or unscheduled visits. Kaplan-Meier (KM) estimates were used to evaluate the median RFS.
| weeks | Obinutuzumab | Mycophenolate Mofetil |
|---|---|---|
| Overall Relapse-free Survival (RFS) | NA (NA to NA) | 93.4 (82.6 to NA) |
Cumulative corticosteroid dose was defined as the total dose received (mg/kg) of prednisone or equivalent, regardless of intercurrent events (relapse, rescue therapy, treatment discontinuation for any reason, and systemic corticosteroid usage for \> 14 days) in participants prior to experiencing death. Topical, intraarticular, or inhaled corticosteroids and IV methylprednisolone given as a pre-medication were not included in this analysis.
| mg/kg | Obinutuzumab | Mycophenolate Mofetil |
|---|---|---|
| Cumulative Corticosteroid Dose From Baseline to Week 52 | 10.07 (3.92 to 26.28) | 18.92 (6.73 to 55.10) |
Relapses were evaluated using adjusted rate ratio from baseline to Week 52, regardless of IEs (relapse, TDAR \& systemic corticosteroid usage for \>14 days) in participants before receiving rescue therapy (RT)/experiencing death. Total number of relapses occurring during treatment period were evaluated by accounting for number of relapses experienced \& participant's follow-up time. Participant level relapse \& follow-up time data were aggregated, \& rate of relapses was compared between the two arms. Rate of relapse was analyzed using a negative binomial model with a log link \& log of each participant's follow up time as offset variable. Relapse=any of the following events: First-morning void UPCR ≥2 g/g; or dipstick UA ≥3+ for 3 consecutive days (home-monitoring) \& most recent urine sample determined to have UPCR \>0.2 g/g as measured by the central laboratory; or dipstick UA protein ≥ 3+ on any single day with edema \& urine sample determined to have UPCR \>0.2 g/g per central laboratory.
| relapses per year | Obinutuzumab | Mycophenolate Mofetil |
|---|---|---|
| Relapses From Baseline to Week 52 | 0.09 | 0.63 |
Sustained complete remission=first morning void UPCR ≤ 0.2 g/g at Week 76 without the occurrence of relapse or any other IE (except TDAR). Relapse=Any of the following events: First-morning void UPCR ≥ 2 g/g; or dipstick UA ≥3+ for 3 consecutive days (home-monitoring) \& the most recent urine sample determined to have UPCR \> 0.2 g/g as measured by the central laboratory; or dipstick UA protein ≥ 3+ on any single day with edema \& urine sample determined to have UPCR \> 0.2 g/g as measured by the central laboratory. Other IEs include: Any systemic corticosteroids usage for \>14 days in a 30 day period; Initiation of any rescue therapy for INS, other than systemic corticosteroids; Death or TDAR. Participants with FRNS/SDNS who were randomized into the study at least 24 weeks prior to the date of randomization for the final participant in the study were only analyzed in this endpoint. Percentages have been rounded off.
| percentage of participants | Obinutuzumab | Mycophenolate Mofetil |
|---|---|---|
| Percentage of Participants With Sustained Complete Remission at Week 76 | 80.0 (62.47 to 97.53) | 61.9 (41.13 to 82.67) |
Probability of RFS at Week 52 was defined as the percentage of participants remaining free of relapse or death at Week 52. Relapse was defined as any of the following events: First-morning void UPCR ≥2 g/g; or dipstick UA ≥3+ for 3 consecutive days (home-monitoring) and the most recent urine sample determined to have UPCR \> 0.2 g/g as measured by the central laboratory; or dipstick UA protein ≥ 3+ on any single day with edema and urine sample determined to have UPCR \> 0.2 g/g as measured by the central laboratory. Participants who withdrew their consent were censored at the time of withdrawal. Participants who were lost to follow-up were censored at the last assessment during scheduled or unscheduled visits. K-M method was used to estimate the RFS rate at Week 52. Percentages have been rounded off.
| percentage of participants | Obinutuzumab | Mycophenolate Mofetil |
|---|---|---|
| Probability of RFS at Week 52 | 90.91 (77.57 to 96.49) | 70.73 (54.26 to 82.19) |
Edema-associated relapse definition is the same as the definition of relapse except that the edema-associated relapse definition additionally requires that participant edema is present and documented in the eCRF at the time of the relapse event. Relapse=any of the following events: First-morning void UPCR ≥ 2 g/g; or dipstick UA ≥3+ for 3 consecutive days (home-monitoring) \& the most recent urine sample determined to have UPCR \> 0.2 g/g, measured by the central laboratory; or dipstick UA protein ≥ 3+ on any single day with edema \& urine sample determined to have UPCR \> 0.2 g/g as measured by the central laboratory. Percentages have been rounded off.
| percentage of participants | Obinutuzumab | Mycophenolate Mofetil |
|---|---|---|
| Percentage of Participants Experiencing Edema Associated Relapse During the 52-week Treatment Period | 2.3 (0.00 to 6.68) | 14.6 (3.82 to 25.45) |
Mean Change in CureGN Edema scale was defined as the mean change in total edema severity from baseline to Week 52, regardless of relapse, systemic corticosteroids usage for \>14 days in a 30 day period, and treatment discontinuation due to any reason, in participants prior to receiving rescue therapy and assuming death has not occurred. The CureGN edema scale was used to assess the total edema severity. Participants were asked to report the location of edema they experienced over the last month from eight different body areas (whole body, face, hands, arms, abdomen, genitalia, legs, feet) and rate its severity on a 6-point Likert scale (0=absent to 5=worst imaginable), with total scores ranging from 0-40. Higher score indicated worst edema severity. Adjusted mean change in the CureGN edema scale scores from baseline to Week 52 has been reported.
| score on a scale | Obinutuzumab | Mycophenolate Mofetil |
|---|---|---|
| Mean Change From Baseline to Week 52 in Cure Glomerulonephropathy Network (CureGN) Edema Scale | -1.66 ± 0.320 | -2.23 ± 0.371 |
Mean Change in "General Fatigue" domain of PedsQL-MFS total score was defined as the mean change in total score of the "General Fatigue" domain from baseline to Week 52, regardless of relapse, systemic corticosteroids usage for \>14 days in a 30-day period, \& treatment discontinuation due to any reason, in participants prior to receiving rescue therapy \& assuming death did not occur. PedsQL MFS is an 18-item, self-reported measure designed to assess fatigue in participants with acute or chronic health conditions. This was a standard version with a 1-month recall period. The measure assessed three components of fatigue: General Fatigue (6 items), Sleep/Rest Fatigue (6 items), \& Cognitive Fatigue (6 items). General fatigue scores were based on a 5-point Likert response format, ranging from 0 (Never) to 4 (Almost Always) \& transformed to 0-100 total score. Higher score=less fatigue. Adjusted mean change in general fatigue domain scores from baseline to Week 52 has been reported.
| score on a scale | Obinutuzumab | Mycophenolate Mofetil |
|---|---|---|
| Mean Change From Baseline to Week 52 in "General Fatigue" Domain of Pediatric Quality of Life Inventory (PedsQL)-Multidimensional Fatigue Scale (MFS) Total Score | 2.05 ± 2.319 | 5.80 ± 2.653 |
Mean Change in PF domain of PedsQL = mean change in the PF score from baseline to Week 52, regardless of relapse, systemic corticosteroids usage for \>14 days in a 30-day period, \& treatment discontinuation due to any reason, in participants prior to receiving rescue therapy \& assuming death did not occur. The PedsQL 4.0 Generic Core Scale is a 23 item measure used to assess health-related quality of life, over a recall of either one month (standard version) or 7 days (acute version). The 4 core domains include PF (8 items), Emotional Functioning (5 items), Social Functioning (5 items), and School Functioning (5 items). Items are rated on a 5-point Likert scale ranging from 0 (never a problem) to 4 (almost always a problem). Once completed, items are reverse scored \& linearly transformed to 0-100 scale as follows: 0=100, 1=75, 2=50, 3=25, 4=0, with higher scores=better health-related quality of life. Adjusted mean change in PF domain scores from baseline to Week 52 has been reported.
| score on a scale | Obinutuzumab | Mycophenolate Mofetil |
|---|---|---|
| Mean Change From Baseline to Week 52 in "Physical Functioning (PF)" Domain of PedsQL-4.0 Generic Core Scale | 5.80 ± 3.062 | 6.15 ± 3.509 |
An AE was defined as any untoward medical occurrence in a participant or clinical study participant temporally associated with the use of a study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study intervention. As pre-specified in the SAP, analysis excludes AEs reported following rescue treatment other than corticosteroids.
| Participants | Obinutuzumab | Mycophenolate Mofetil |
|---|---|---|
| 52-week Treatment Period: Number of Participants With Adverse Events (AEs) | 42 | 34 |
Samples were collected pre- and post-infusion at Weeks 0, 2, 24, and 26 and single samples were collected at Weeks 4, 12, 32, and 52. Data reported is averaged over the weeks specified in the time frame.
| μg/mL | Obinutuzumab |
|---|---|
| Weeks 0-24 | 757 ± 24.2 |
| Weeks 24-52 | 668 ± 23.2 |
Samples were collected pre- and post-infusion at Weeks 0, 2, 24, and 26 and single samples were collected at Weeks 4, 12, 32, and 52. Data reported is averaged over the weeks specified in the time frame.
| μg/mL | Obinutuzumab |
|---|---|
| Weeks 0-24 | 7.96 ± 82.4 |
| Weeks 24-52 | 7.44 ± 72.1 |
Samples were collected pre- and post-infusion at Weeks 0, 2, 24, and 26 and single samples were collected at Weeks 4, 12, 32, and 52. Data reported is averaged over the weeks specified in the time frame.
| μg/mL*day | Obinutuzumab |
|---|---|
| Area Under the Concentration-Time Curve of Obinutuzumab From Time 0 to 52 Weeks (AUC0-52) | 68,000 ± 27.4 |
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Collected over AEs and SAEs: Up to Week 52 All-cause Mortality: Up to approximately 127.3 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Obinutuzumab | 0/44 (0%) | 7/44 (15.9%) | 42/44 (95.5%) |
| Mycophenolate Mofetil | 0/41 (0%) | 3/41 (7.3%) | 34/41 (82.9%) |
| Event | Obinutuzumab | Mycophenolate Mofetil |
|---|---|---|
| PneumoniaInfections and infestations | 2/44 | 0/41 |
| Abdominal distensionGastrointestinal disorders | 0/44 | 1/41 |
| Gastrointestinal infectionInfections and infestations | 0/44 | 1/41 |
| Viral upper respiratory tract infectionInfections and infestations | 0/44 | 1/41 |
| Neutrophil count decreasedInvestigations | 0/44 | 1/41 |
| Nephrotic syndromeRenal and urinary disorders | 0/44 | 1/41 |
| AgranulocytosisBlood and lymphatic system disorders | 1/44 | 0/41 |
| LymphadenitisBlood and lymphatic system disorders | 1/44 | 0/41 |
| NeutropeniaBlood and lymphatic system disorders | 1/44 | 0/41 |
| Lower respiratory tract infection viralInfections and infestations | 1/44 | 0/41 |
| Event | Obinutuzumab | Mycophenolate Mofetil |
|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 13/44 | 15/41 |
| Infusion related reactionInjury, poisoning and procedural complications | 16/44 | 0/41 |
| InfluenzaInfections and infestations | 9/44 | 4/41 |
| PyrexiaGeneral disorders | 8/44 | 5/41 |
| CoughRespiratory, thoracic and mediastinal disorders | 8/44 | 5/41 |
| NasopharyngitisInfections and infestations | 4/44 | 7/41 |
| Ear infectionInfections and infestations | 7/44 | 3/41 |
| PneumoniaInfections and infestations | 7/44 | 2/41 |
| BronchitisInfections and infestations | 6/44 | 2/41 |
| SinusitisInfections and infestations | 6/44 | 3/41 |
Efficacy-evaluable (EE) population included all randomized participants, whether or not the participant received the assigned treatment.
| Age, Continuous(years) | Obinutuzumab | Mycophenolate Mofetil | Total |
|---|---|---|---|
| Mean | 10.4 ± 4.4 | 9.3 ± 4.4 | 9.9 ± 4.4 |
| Sex: Female, Male(Participants) | Obinutuzumab | Mycophenolate Mofetil | Total |
|---|---|---|---|
| Female | 16 | 14 | 30 |
| Male | 28 | 27 | 55 |
| Ethnicity (NIH/OMB)(Participants) | Obinutuzumab | Mycophenolate Mofetil | Total |
|---|---|---|---|
| Hispanic or Latino | 11 | 10 | 21 |
| Not Hispanic or Latino | 33 | 31 | 64 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Obinutuzumab | Mycophenolate Mofetil | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 8 | 15 | 23 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 7 | 5 | 12 |
| White | 28 | 19 | 47 |
| More than one race | 1 | 1 | 2 |
| Unknown or Not Reported | 0 | 1 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing
Ran from Mar 2023 to primary completion in Sep 2025, 29 months.
Results were first posted in Oct 2026, 1 year 1 month after primary completion.
Completion moved once since we started tracking on Sep 25, 2026: Sep 2026 → Aug 2026, on Oct 14, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Obinutuzumab